• gmp-verlag.de
  • GMP MANUAL Login
  • Shopping cart
Stay informed!

If you’d like to be regularly informed of the latest developments at Good Manufacturing Practices


>>> REGISTER for our free GMP Newsletter LOGFILE


TOP 5 GMP Downloads

1. Quality Agreement
Defines framework conditions and processes between contract givers and contract acceptors in order to meet mandatory quality criteria.


2. GDP Audit Checklist
More than 700 questions with reference to regulations for preparing and carrying out GDP audits.


3. GMP Audit Checklist
The GMP Audit Checklist works great for both sides - the auditor and the inspected company.


4. Technical Agreement
and Delimination of Pharmaceutical Responsibilities.


5. A Process Approach to Pharmaceutical Quality Systems
A Guide to ICH Q10 Compliance


Your benefits:

> no shipping costs
> no waiting period: if you choose payment by credit card you will receive an email with the download information immediately after payment.


>>> Click here to find more Downloads!

News about GMP/cGMP


The ICH has published the final version of the Q&A document to the ICH Q7 Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. The document was prepared by the Q7 Implementation Working Group in order to clarify uncertainties related to the interpretation of some sections.


As previously announced by the ICH, new training material to ICH documents will be published and updated on the ICH website on a regularly basis. The intention behind this supporting service is to facilitate the implementation of ICH Guidelines by resolving uncertainties which have arisen during the application of the guideline.


The WHO has published the final versions of the

Both documents were released as part of the Technical Report Series 992, which was published by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in May 2015.


The WHO has published an interesting new Guidance named “Technical supplements to Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products”.  The target readership includes regulators, logisticians and pharmaceutical professionals in industry, government and international agencies.


The FDA has issued the draft guidance “Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products”. This guidance has been developed to address a lack of clarity concerning chemistry, manufacturing, and controls (CMC) in a marketing application. It explains whether CMC information represents an established condition or a “regulatory commitment” that, if changed following approval, requires reporting to the FDA.


The EMA has released a concept paper on new guidance for importers of medicinal products. GMP/GDP Inspectors Working Group agreed to draft a specific guidance for import authorisation holders. This document most likely would take the form of a new annex (Annex 21). The deadline for comments is 29 August 2015.


The ICH Steering Committee (SC) will meet in Fukuoka, Japan from 6 to 11 June to discuss ongoing harmonisation activities. One item on the agenda is the development of the ICH Q12 Guideline on Lifecycle Management.


The IPEC Federation (International Pharmaceutical Excipients Council) has published a three-page position paper concerning the risk-based approach of the EU Guidelines following the principles of Quality Risk Management according to ICH Q9. The IPEC-paper applies to the community regulated under the EU Risk Assessment Guidelines.


The European Commission has published the responses to the public consultation on the revision of Annex 15: Qualification and Validation.


Following a three years period since publishing the “Biologics Price Competition and Innovation Act” and therein the “Approval Pathway for Biosimilar Biological Products”, the FDA has now finalized the following three guidance documents on Biosimilars:

Guidance for Industry - Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Guidance for Industry - Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product

Guidance for Industry - Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.


For many years now, discussions have been ongoing as to whether it is possible to include non-distillation technologies as a method for the production of Water for Injections (WFI). Following a number of consultations with its stakeholders, the Ph. Eur. is proposing a revision of the monograph for Water for Injections (0169) to take into account current manufacturing practices which use methods other than distillation to produce water of injectable quality. The draft of the monograph foresees production of WFI also by reverse osmosis, which may be single-pass or double-pass, coupled with other suitable techniques such as deionisation and/or ultrafiltration.


As announced on the website of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), the PIC/S Committee, by written procedure, has adopted the revision of Annex 15 of the PIC/S GMP Guide. The document will enter into force on 1 October 2015, simultaneously to the EU revision of Annex 15.


The currently valid version of the EU GMP Guide  Annex 15 “Qualification and Validation” from 2001 will finally be replaced by 1 October 2015. This is when the now published revised Version of Annex 15 will enter into force. An update was more than necessary. Not only the new principles of ICH Q8, Q9, Q10 and Q11 constituted a new regulatory environment but also a continuous updating of Chapters of Part I of the EU GMP Guide or Annex 11 (computerised systems). Another important document to be mentioned in connection with the new Annex 15 is the EMA guidance on process validation. The changes now reflect the changed regulatory requirements and the latest state of technology in the pharmaceutical industry.


On 20 March 2015 the WHO has published a report on substandard/spurious/falsely-labelled/falsified/counterfeit medicinal products (SSFFCs). The report was developed during a Member State Meeting on SSFFC in October 2014 in Geneva, Switzerland. It includes recommendations for health authorities to detect and deal with actions, activities and behaviours that result in SSFFCs.

Page 1/29    1   2   3   4   5   6   7   8   9   10